Andrew Altman Net Worth

The estimated Net Worth of Andrew Altman is at least $251 mil dollars as of 31 January 2018. Andrew Altman owns over 50,000 units of SenesTech Inc stock worth over $250,740 and over the last 7 years Andrew sold SNES stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Andrew Altman SNES stock SEC Form 4 insiders trading

Andrew has made over 4 trades of the SenesTech Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently Andrew exercised 50,000 units of SNES stock worth $160,500 on 31 January 2018.

The largest trade Andrew's ever made was exercising 50,000 units of SenesTech Inc stock on 31 January 2018 worth over $160,500. On average, Andrew trades about 16,000 units every 34 days since 2017. As of 31 January 2018 Andrew still owns at least 78,112 units of SenesTech Inc stock.

You can see the complete history of Andrew Altman stock trades at the bottom of the page.

What's Andrew Altman's mailing address?

Andrew's mailing address filed with the SEC is # 1, 9428, 3140 N Caden Ct, Flagstaff, AZ 86004, United States.

Insiders trading at SenesTech Inc

Over the last 8 years, insiders at SenesTech Inc have traded over $262,233 worth of SenesTech Inc stock and bought 999,146 units worth $1,973,633 . The most active insiders traders include Grover T Wickersham, Kenneth S Siegel, eJacob Steven Leach. On average, SenesTech Inc executives and independent directors trade stock every 24 days with the average trade being worth of $74,077. The most recent stock trade was executed by Jacob Steven Leach on 16 August 2021, trading 150,000 units of SNES stock currently worth $229,500.

What does SenesTech Inc do?

senestech is changing the paradigm of pest management by targeting the root cause of the problem: reproduction. contrapest® is an innovative technology that targets the reproductive capabilities of norway and roof rats. as a highly palatable liquid, the formulation promotes sustained consumption, helping to reduce fertility in both male and female rats, bringing populations down and keeping them down. our delivery system is designed to minimize handler exposure, and contrapest® is dispensed inside tamper resistant bait stations, minimizing the risks to non-target species. as a versatile tool, contrapest® can be used within your integrated pest management program to help reduce reproduction and magnify the success of your ipm protocols or as a standalone, non-lethal solution for customers that are looking to reduce or eliminate their use of lethal methodologies. contrapest® is a restricted use pesticide, due to applicator expertise. please read and comply with all label instructions. fo

Complete history of Andrew Altman stock trades at SenesTech Inc

SenesTech Inc executives and stock owners

SenesTech Inc executives and other stock owners filed with the SEC include:

• Kenneth Siegel,
  Chief Executive Officer, Director
• Kenneth S. Siegel,
  CEO & Director
• Thomas Chesterman,
  Chief Financial Officer, Executive Vice President, Treasurer, Assistant Secretary
• Thomas C. Chesterman M.B.A.,
  Exec. VP, CFO, Treasurer & Assistant Sec.
• Thomas C. Chesterman,
  Exec. VP, CFO, Treasurer & Assistant Sec.
• Dr. Steven C. Krause Ph.D.,
  Exec. VP of Sales & Marketing
• Kim Wolin,
  Executive Vice President - Operations, Secretary
• Jamie Morrison,
  Independent Chairman of the Board
• Kim Patrice Wolin,
  Exec. VP of Operations & Sec.
• Jake Leach,
  Independent Director
• K. Kavanagh,
  Independent Director
• Phil Grandinetti,
  Independent Director
• Julia Williams,
  Independent Director
• Matthew Szot,
  Independent Director
• Marc Dumont,
  Independent Director
• Delphine Chiavarini,
  Independent Director
• Steve Krause,
  Executive Vice President of Sales and Marketing
• Nicole Williams,
  Chief Strategy Officer
• Robert Blum,
  Investor Relations
• Paul M. Palz,
  VP & Corp. Controller
• Loretta Powers Mayer,
  Chief Scientific Officer
• Grover T Wickersham,
  Director
• Robert E Jr Ramsey,
  Director
• Cheryl Ann Dyer,
  Pres. & Chief Research Officer
• Jacob Steven Leach,
  Director
• Nicole C Williams,
  Chief Strategy Officer
• Joel Lee Fruendt,
  Chief Executive Officer